Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 7/20 | 0.34 |
| ▸ | BTK | Q06187 | 7/20 | 0.34 |
| ▸ | TXK | P42681 | 6/20 | 0.34 |
| ▸ | ITK | Q08881 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | USP2 | O75604 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1341758 | 0.89 | LMNA (0.41) | NPC1KMT2AJAK3BTKTXK | |
| SCHEMBL1342056 | 0.89 | DCUN1D1 (0.35) | JAK3BTKTXKITKLMNA | |
| SCHEMBL1341776 | 0.88 | NPC1 (0.38) | NPC1KMT2AMAPTLMNAUSP2 | |
| SCHEMBL6694773 | 0.83 | MAPK14 (0.39) | MAPT | |
| SCHEMBL1341055 | 0.83 | ALDH1A1 (0.41) | NPC1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL1339277 | 0.82 | GCK (0.43) | KMT2AJAK3BTKTXKITK | |
| SCHEMBL1343743 | 0.81 | MAPK14 (0.34) | NPC1MAPTLMNAUSP2ALDH1A1 | |
| SCHEMBL1340880 | 0.81 | CDK2 (0.39) | KMT2AJAK3TXKITKMAPT | |
| SCHEMBL1340727 | 0.81 | TXK (0.37) | JAK3BTKTXKITKSMN1; SMN2 | |
| SCHEMBL1341500 | 0.80 | MAPT (0.37) | KMT2AJAK3BTKTXKITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183783-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2006-08-17 | — | — | US | claimed |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-06-24 | — | — | US | claimed |
| US-RE45670-E1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2015-09-15 | — | — | US | disclosed |
| US-RE45670-E1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2015-09-15 | — | — | US | disclosed |
| EP-2471533-A1 | Aryl carbonyl derivatives as therapeutic agents | Novo Nordisk A/S (DK) | 2012-07-04 | — | — | EP | disclosed |
| EP-2471533-A1 | Aryl carbonyl derivatives as therapeutic agents | Novo Nordisk A/S (DK) | 2012-07-04 | — | — | EP | disclosed |
| US-20110301158-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | NOVO NORDISK A/S (DK) | 2011-12-08 | — | — | US | disclosed |
| US-20110301158-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | NOVO NORDISK A/S (DK) | 2011-12-08 | — | — | US | disclosed |
| US-8063081-B2 | N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-11-22 | — | — | US | disclosed |
| US-8063081-B2 | N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-11-22 | — | — | US | disclosed |
| US-8063081-B2 | N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-11-22 | — | — | US | disclosed |
| US-20080119454-A1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-05-22 | — | — | US | disclosed |
| US-20080119454-A1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-05-22 | — | — | US | disclosed |
| US-20080119454-A1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-05-22 | — | — | US | disclosed |
| US-20080119455-A1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-05-22 | — | — | US | disclosed |
| US-20060183783-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2006-08-17 | — | — | US | disclosed |
| EP-1531815-A1 | GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2005-05-25 | — | — | EP | disclosed |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-06-24 | — | — | US | disclosed |
| WO-2004002481-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | NOVO NORDISK A/S (DK) | 2004-01-08 | — | — | WO | disclosed |
| WO-2004002481-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | NOVO NORDISK A/S (DK) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301158-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | GCK, GCKR, PDK2 | NPC1 2201/4885KMT2A 1526/4885JAK3 3403/4885 |
| US-20080119455-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | NPC1 2201/4885KMT2A 1526/4885JAK3 3403/4885 |
| US-20060183783-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, PDK3, PDK4 | NPC1 2499/4885KMT2A 1719/4885JAK3 3276/4885 |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | NPC1 2201/4885KMT2A 1526/4885JAK3 3403/4885 |
| US-20080119454-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | NPC1 2201/4885KMT2A 1526/4885JAK3 3403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.